Navigation Links
Epinomics to Collaborate with the Parker Institute for Cancer Immunotherapy at Stanford University to Bring Precision Medicine to Cancer Immunotherapies
Date:2/8/2017

MENLO PARK, Calif., Feb. 8, 2017 /PRNewswire/ -- Researchers from Epinomics will collaborate with the research team led by Crystal Mackall, MD, director of the Parker Institute for Cancer Immunotherapy at Stanford, to utilize biomarkers defined by Epinomics' immune intelligence framework to improve outcome and reduce adverse events in immunotherapy clinical trials.

"The insights from this work will serve to direct further improvements for these therapeutics that will be pursued at Stanford and the set of biomarkers will be employed in clinical use moving forward," said Fergus Chan, MBA, who co-founded Epinomics in 2013. "Joining forces with Dr. Mackall and her team at Stanford will enable us to bring precision medicine to these immunotherapies."

The Parker Institute for Cancer Immunotherapy at Stanford University opened in April thanks to a grant from the Parker Foundation, which was started by entrepreneur Sean Parker. "We are very excited to be collaborating with Epinomics," Dr. Mackall said. "I know we will benefit greatly from the expertise Epinomics has in the epigenomics field, including their analytics platform that is advancing therapeutic development efforts and discovery of biomarkers for use in clinical care for immuno-oncology applications."

The epigenome ("the living genome") refers to any modification to the genome without changes to the DNA sequence, and it regulates what genes are turned on and off.  If the genome, which shows what genes we have, is the hardware of our bodies, then epigenome is the software programming layer of our bodies. Because the epigenome dynamically responds to the environment and reflects one's current health state, it holds the key to personalized medicine.

Paul Giresi, PhD, another co-founder of Epinomics, notes that immunotherapy has been shown to be a promising approach for the effective treatment of cancer, including achieving long term remission in patients who have not responded to existing therapies. But to date there is no gold standard for the application or monitoring for this type of therapy. "The key to unlocking this potential in immuno-oncology has been the development of a new technology for reading the epigenome and creation of a deep analytics framework that serves as a central intelligence hub for understanding immune function in human health and disease. Using this framework can derive measures (biomarkers) of immune function across both healthy baseline samples and disease to enable investigators to pinpoint the key immunological features that are the drivers of human disease and are predictive of clinical outcomes," Dr. Giresi said.

ABOUT EPINOMICS INC.

Epinomics' vision is to create a comprehensive map of human health states, and leverage epigenomics technology and deep analytics to develop a GPS to guide personalized health.

After decades of research by the genomics communities, professors and scientists at Stanford's University, including Paul Giresi, PhD, Howard Chang, MD, PhD and William Greenleaf, PhD invented a breakthrough technology that can decode the epigenome - ATAC-seq (Assay for Transposase-Accessible Chromatin with high throughput sequencing).

In 2013, Fergus Chan and Paul Giresi, co-founded Epinomics, together with Drs. Chang and Greenleaf as the company's scientific co-founders. Epinomics' proprietary technology and deep analytics has attracted demand and collaboration interests across top pharmaceutical, biotech companies, as well as leading research institutes, where Epinomics enables them to advance their therapeutics development or co-develop clinical applications.

Epinomics' scientific advisory board includes Michael Snyder, MD, (Chair of Stanford's Genetics Department), Joseph R. Ecker, PhD (Salk International Council Chair in Genetics, HHMI) Anshul Kundaje (a leader of NIH-funded ENCODE and Epigenomics Roadmap Consortia) and Robert Tibshirani (Professor of Health Research and Policy, and Statistics at Stanford).  As the frontier of the field, Epinomics has been working with thought leaders in creating standards and advancing epigenomics applications towards personalized medicine, which include building standard-compatible analytics pipelines for researchers through working with NIH-funded Encyclopedia of DNA Elements (ENCODE) leaders.

www.epinomics.co

About the Parker Institute for Cancer Immunotherapy

The Parker Institute for Cancer Immunotherapy brings together the best scientists, clinicians, and industry partners to build a smarter and more coordinated cancer immunotherapy research effort.

The Parker Institute is an unprecedented collaboration between the country's leading immunologists and cancer centers: Memorial Sloan Kettering Cancer Center, Stanford Medicine, the University of California, Los Angeles, the University of California, San Francisco, the University of Pennsylvania and The University of Texas MD Anderson Cancer Center. The Parker Institute was created through a $250 million grant from The Parker Foundation.

The Parker Institute's goal is to accelerate the development of breakthrough immune therapies capable of turning cancer into a curable disease by ensuring the coordination and collaboration of the field's top researchers, and quickly turning their findings into patient treatments. The Parker Institute network brings together six centers, more than 40 labs and more than 300 of the nation's top researchers focused on treating the deadliest cancers.

www.parkerici.org

Contact:
Fergus Chan
Science: epi@epinomics.co 
Media: press@epinomics.co

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/epinomics-to-collaborate-with-the-parker-institute-for-cancer-immunotherapy-at-stanford-university-to-bring-precision-medicine-to-cancer-immunotherapies-300403849.html


'/>"/>
SOURCE Epinomics
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Caris Life Sciences and the Lustgarten Foundation Collaborate to Support Immunotherapy Clinical Trial for Pancreatic Cancer
2. Johnson & Johnson Innovation, New York State and New York Genome Center Collaborate to Launch JLABS in New York City
3. Almac Group Collaborates with Exostar to Extend Clinical Trials with Interactive Response Technology
4. Merck Collaborates with Evotec for Faster Target Identification Solution
5. UCSF and Berkeley Lights Collaborate on Single-Cell Genomics
6. ACRES and GuideStar Collaborate on Biomedical Research Site Sustainability
7. Admetsys Collaborates with Hospira to Prevent Hypoglycemia in Patients at Diabetic Risk
8. ACRES and ActivMed Collaborate on Clinical Research Site Standards and Sustainability
9. PTC Therapeutics and Massachusetts General Hospital Collaborate on Rare Disease Research
10. RGP, Resilinc to Collaborate on Conflict Minerals Rule Webcast Event
11. ARCH Venture Partners, Flagship Ventures and MD Anderson Collaborate to Launch Codiak BioSciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... market and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase ... "The residential security market has experienced continued growth, ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... (PRWEB) , ... October 09, ... ... published on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s ... the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using ...
(Date:10/6/2017)... (PRWEB) , ... October 06, 2017 , ... ... entrepreneurship within the healthcare and technology sector at their fourth annual Conference where ... featuring 30 inspiring speakers and the ELEVATE pitch competition showcasing early stage digital ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
Breaking Biology News(10 mins):